Just saw that AbbVie pushed Rinvoq through to the FDA and EMA for vitiligo treatment. Pretty interesting move - they're going after non-segmental vitiligo specifically based on their Phase 3 data showing solid repigmentation results. The trial hit both endpoints: 50% improvement in total body repigmentation and 75% in facial areas by week 48. That's actually a meaningful outcome for a condition that doesn't have a ton of treatment options.

Rinvoq has already been doing work in rheumatoid arthritis and inflammatory bowel disease, so AbbVie's basically expanding its footprint into dermatology. The vitiligo indication could be a decent revenue driver if it gets approved. Stock was up a bit when this news dropped, though that was a while back now.

Anyone else following vitiligo treatment developments? Seems like there's been more activity in this space lately. The unmet need is definitely there for patients dealing with it.